While ccRCC is not typically associated with canonical MAPK/ERK driver mutations, aberrant activation of this pathway has been implicated in resistance to both VEGF-targeted therapies and immune checkpoint inhibitors. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.